NCT04711850View on ClinicalTrials.gov

An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR

TerminatedOBSERVATIONAL
Enrollment

18

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

March 30, 2023

Study Completion Date

March 30, 2023

Conditions
Kidney Transplant Rejection
Interventions
DRUG

Imlifidase

Immunoglobulin G degrading enzyme of Streptococcus pyogenes

Trial Locations (7)

1090

Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie MUW, Vienna

13353

Charité-Universitätsmedizin. Dept. of Nephrology and Medical Intensive Care, Berlin

33076

Hôpital Pellegrin, Bordeaux

38043

CHU Grenoble Alpes - Néphrologie, dialyse et transplantation, Grenoble

75475

Hôpital Saint-Louis. Service de Néphrologie et Transplantation, Paris

75742

Hôpital Necker - Service de Néphrologie - Transplantation, Paris

Unknown

Medizinische Hochschule Hannover, Hanover

Sponsors

Lead Sponsor

Hansa Biopharma AB
All Listed Sponsors
lead

Hansa Biopharma AB

INDUSTRY

NCT04711850 - An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR | Biotech Hunter | Biotech Hunter